Haemonetics Corporation (HAE)
Profitability ratios
Return on sales
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 55.04% | 52.97% | 52.29% | 52.10% | 52.50% | 52.90% | 52.67% | 52.53% | 52.63% | 52.70% | 53.06% | 52.59% | 50.90% | 47.31% | 46.34% | 46.04% | 45.70% | 48.60% | 48.46% | 48.50% |
| Operating profit margin | 16.30% | 14.68% | 13.85% | 12.91% | 14.22% | 13.40% | 13.52% | 14.68% | 13.35% | 12.40% | 12.21% | 10.73% | 8.13% | 4.24% | 4.83% | 8.79% | 10.31% | 15.49% | 15.23% | 13.58% |
| Pretax margin | 15.58% | 11.99% | 11.67% | 11.02% | 11.60% | 12.68% | 12.85% | 13.75% | 12.10% | 10.99% | 10.45% | 8.98% | 6.41% | 2.19% | 2.88% | 6.85% | 8.38% | 13.83% | 13.60% | 11.93% |
| Net profit margin | 12.32% | 9.47% | 9.10% | 8.61% | 8.98% | 9.97% | 10.35% | 11.21% | 9.87% | 8.48% | 7.94% | 6.60% | 4.37% | 2.37% | 3.35% | 7.14% | 9.13% | 12.23% | 11.76% | 10.10% |
Haemonetics Corporation's profitability ratios have shown some fluctuations over the quarters. The Gross Profit Margin has generally been increasing from 48.50% in June 2020 to 55.04% in March 2025, indicating the company's ability to control production costs and generate more profit from sales.
The Operating Profit Margin varied significantly, with a peak of 16.30% in March 2025. This ratio reflects the company's operational efficiency in generating profits from its core business activities.
The Pretax Margin also experienced fluctuations but generally showed an increasing trend, reaching 15.58% in March 2025. This ratio demonstrates the company's ability to manage expenses and generate profits before taxes.
The Net Profit Margin also displayed fluctuations but showed an upward trend overall, increasing from 10.10% in June 2020 to 12.32% in March 2025. This ratio reflects the company's effectiveness in converting revenue into net income after accounting for all expenses.
Overall, Haemonetics Corporation's profitability ratios indicate an improving trend over the quarters, with increasing margins in Gross Profit, Operating Profit, Pretax Profit, and Net Profit. This suggests that the company has been successful in managing costs, increasing operational efficiency, and generating higher profits relative to sales.
Return on investment
| Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 9.05% | 7.97% | 7.47% | 6.78% | 8.48% | 7.73% | 8.33% | 9.12% | 8.06% | 7.45% | 7.10% | 6.05% | 4.34% | 2.20% | 2.51% | 4.43% | 4.93% | 10.39% | 9.69% | 8.96% |
| Return on assets (ROA) | 6.84% | 5.14% | 4.90% | 4.52% | 5.35% | 5.75% | 6.38% | 6.96% | 5.96% | 5.10% | 4.61% | 3.72% | 2.33% | 1.23% | 1.73% | 3.59% | 4.37% | 8.20% | 7.48% | 6.67% |
| Return on total capital | 12.74% | 19.01% | 18.13% | 18.22% | 18.63% | 17.28% | 17.93% | 20.69% | 19.08% | 18.04% | 18.14% | 14.28% | 10.76% | 5.51% | 6.46% | 11.73% | 12.27% | 19.04% | 20.57% | 21.09% |
| Return on equity (ROE) | 17.62% | 14.34% | 14.09% | 12.69% | 12.25% | 13.42% | 14.35% | 15.79% | 14.11% | 12.34% | 11.80% | 8.79% | 5.79% | 3.09% | 4.47% | 9.52% | 10.86% | 15.04% | 15.89% | 15.70% |
Haemonetics Corporation's profitability ratios show fluctuations over the reported periods.
- The Operating Return on Assets (Operating ROA) has varied between 2.2% and 10.39%, with the highest point recorded as 10.39% on December 31, 2020. It indicates how efficiently the company generates profits from its assets used in operations.
- The Return on Assets (ROA) shows a range from 1.23% to 8.20%, with the peak at 8.20% on December 31, 2020. This ratio reflects the company's ability to generate profits from its total assets.
- The Return on Total Capital ranged from 5.51% to 21.09%, reaching the highest at 21.09% on June 30, 2020. This ratio assesses the company's ability to generate returns for all its capital providers.
- The Return on Equity (ROE) varied between 3.09% and 17.62%, with the maximum at 17.62% recorded on March 31, 2025. This ratio indicates the profitability derived for the shareholders' equity invested in the company.
Overall, Haemonetics Corporation's profitability ratios demonstrate fluctuations but generally show a positive trend in generating returns for its assets, capital, and equity over the reported periods.